Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: A review

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Osayi, Sylvester N ^a   Bloomston, Mark ^a   Schmidt, Carl M ^a   Ellison, E Christopher ^a   Muscarella, Peter ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

CANCER GROWTH; CANCER SURGERY; CIRCULATING TUMOR CELL; DISEASE MARKER; EXTRACELLULAR MATRIX; HUMAN; IMMUNOREACTIVITY; LIVER METASTASIS; MEDLINE; META ANALYSIS; NEUTROPHIL; NEUTROPHIL TO LYMPHOCYTE RATIO; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PATIENT CARE; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE; UNITED STATES; ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; METABOLISM; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; HUMANS; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904159265     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/468959     Document Type: Review

References (74)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2013. CA Cancer Journal for Clinicians 2013 63 1 11 30 2-s2.0-84872967522 10.3322/caac.21166
2. Ueno H., Kosuge T., Matsuyama Y., Yamamoto J., Nakao A., Egawa S., Doi R., Monden M., Hatori T., Tanaka M., Shimada M., Kanemitsu K., A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. The British Journal of Cancer 2009 101 6 908 915 2-s2.0-70249099504 10.1038/sj.bjc.6605256
3. Conlon K. C., Klimstra D. S., Brennan M. F., Long-term survival after curative resection for pancreatic ductal adenocarcinoma: clinicopathologic analysis of 5-year survivors. Annals of Surgery 1996 223 3 273 279 2-s2.0-0029991497 10.1097/00000658-199603000-00007 (Pubitemid 26086718)
4. Richter A., Niedergethmann M., Sturm J. W., Lorenz D., Post S., Trede M., Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-Year experience. World Journal of Surgery 2003 27 3 324 329 2-s2.0-0038644769 10.1007/s00268-002-6659-z (Pubitemid 36920145)
5. Harsha H. C., Kandasamy K., Ranganathan P., Rani S., Ramabadran S., Gollapudi S., Balakrishnan L., Dwivedi S. B., Telikicherla D., Selvan L. D. N., Goel R., Mathivanan S., Marimuthu A., Kashyap M., Vizza R. F., Mayer R. J., DeCaprio J. A., Srivastava S., Hanash S. M., Hruban R. H., Pandey A., A compendium of potential biomarkers of pancreatic cancer. PLoS Medicine 2009 6 4 2-s2.0-65449141024 10.1371/journal.pmed.1000046 e1000046
6. Moher D., Liberati A., Tetzlaff J., Altman D. G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine 2009 6 7 e1000097
7. Sugiura T., Uesaka K., Kanemoto H., Mizuno T., Sasaki K., Furukawa H., Matsunaga K., Maeda A., Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. Journal of Gastrointestinal Surgery 2012 16 5 977 985 2-s2.0-84865330539 10.1007/s11605-012-1859-9
8. Kang C. M., Kim J. Y., Choi G. H., Kim K. S., Choi J. S., Lee W. J., Kim B. R., The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. Journal of Surgical Research 2007 140 1 31 35 2-s2.0-34247620806 10.1016/j.jss.2006.10.007 (Pubitemid 46669540)
9. Tian F., Appert H. E., Myles J., Howard J. M., Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Annals of Surgery 1992 215 4 350 355 2-s2.0-0026505161
10. Hata S., Sakamoto Y., Yamamoto Y., Nara S., Esaki M., Shimada K., Kosuge T., Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Annals of Surgical Oncology 2012 19 2 636 641 2-s2.0-84860420700 10.1245/s10434-011-2020-9
11. Hernandez J. M., Cowgill S. M., Al-Saadi S., Collins A., Ross S. B., Cooper J., Villadolid D., Zervos E., Rosemurgy A., CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. Journal of Gastrointestinal Surgery 2009 13 2 349 353 2-s2.0-59149084072 10.1007/s11605-008-0696-3
12. Kelly K. J., Wong J., Gladdy R., Moore-Dalal K., Woo Y., Gonen M., Brennan M., Allen P., Fong Y., Coit D., Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection. Annals of Surgical Oncology 2009 16 12 3333 3339 2-s2.0-71549119822 10.1245/s10434-009-0683-2
13. Mataki Y., Takao S., Maemura K., Mori S., Shinchi H., Natsugoe S., Aikou T., Carcinoembryonic antigen messenger RNA expression using nested reverse transcription-PCR in the peripheral blood during follow-up period of patients who underwent curative surgery for biliary pancreatic cancer: longitudinal analyses. Clinical Cancer Research 2004 10 11 3807 3814 2-s2.0-2542524777 10.1158/1078-0432.CCR-03-0130 (Pubitemid 38697616)
14. Garcea G., Ladwa N., Neal C. P., Metcalfe M. S., Dennison A. R., Berry D. P., Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World Journal of Surgery 2011 35 4 868 872 2-s2.0-79952183487 10.1007/s00268-011-0984-z
15. Oshima M., Okano K., Muraki S., Haba R., Maeba T., Suzuki Y., Yachida S., Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Annals of Surgery 2013 258 2 336 346 2-s2.0-84880571709 10.1097/SLA.0b013e3182827a65
16. Nagai K., Doi R., Katagiri F., Ito T., Kida A., Koizumi M., Masui T., Kawaguchi Y., Tomita K., Oishi S., Fujii N., Uemoto S., Prognostic value of metastin expression in human pancreatic cancer. Journal of Experimental and Clinical Cancer Research 2009 28 1, article 9 2-s2.0-60149108488 10.1186/1756-9966-28-9
17. Foo W. C., Rashid A., Wung H., Katz M. H., Lee J. E., Pisters P. W., Wolff R. A., Abbruzzese J. L., Fleming J. B., Wang H., Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Human Pathology 2013 44 6 1024 1030 2-s2.0-84878114129 10.1016/j.humpath.2012.09.001
18. Bachet J. B., Maréchal R., Demetter P., Bonnetain F., Couvelard A., Svrcek M., Bardier-dupas A., Hammel P., Sauvanet A., Louvet C., Paye F., Rougier P., Penna C., Vaillant J. C., André T., Closset J., Salmon I., Emile J. F., Van laethem J. L., Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Annals of Oncology 2012 23 9 2327 2335 2-s2.0-84863542976 10.1093/annonc/mdr617
19. Niedergethmann M., Wostbrock B., Sturm J. W., Willeke F., Post S., Hildenbrand R., Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 2004 29 3 204 211 2-s2.0-4644236863 10.1097/00006676-200410000-00005 (Pubitemid 39304977)
20. Niedergethmann M., Hildenbrand R., Wostbrock B., Hartel M., Sturm J. W., Richter A., Post S., High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002 25 2 122 129 2-s2.0-0036311535 10.1097/00006676-200208000-00002 (Pubitemid 34815907)
21. Jamieson N. B., Morran D. C., Morton J. P., Ali A., Dickson E. J., Carter C. R., Sansom O. J., Evans T. R. J., McKay C. J., Oien K. A., MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research 2012 18 2 534 545 2-s2.0-84855996930 10.1158/1078-0432.CCR-11-0679
22. Winter J. M., Yeo C. J., Brody J. R., Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. Journal of Surgical Oncology 2013 107 1 15 22 2-s2.0-84871298277 10.1002/jso.23192
23. Koprowski H., Steplewski Z., Mitchell K., Herlyn M., Herlyn D., Fuhrer P., Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genetics 1979 5 6 957 971 2-s2.0-0018578870 10.1007/BF01542654 (Pubitemid 10132218)
24. Bloomston M., Bekaii-Saab T. S., Kosuri K., Cowgill S. M., Melvin W. S., Ellison E. C., Muscarella P. II, Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. Pancreas 2006 33 3 246 249 2-s2.0-33749120966 10.1097/01.mpa. 0000236726.34296.df (Pubitemid 44470139)
25. Muscarella P. II, Fisher W., Johnson J. A., Melvin W. S., Lott J. A., Neoplastic disorders of the pancrease. Clinical Pathology of Pancreatic Disorders 1997 Totowa, NJ, USA Humana Press 125 163
26. Lamerz R., Role of tumour markers, cytogenetics. Annals of Oncology 1999 10 4 S145 S149 2-s2.0-0032783998 (Pubitemid 29333419)
27. Woods M. S., Traverso L. W., Kozarek R. A., Tsao J., Rossi R. L., Gough D., Donohue J. H., Way L. W., Hunter J., Vogel S. B., Meyers W. C., Roslyn J. J., Sonneland J., Characteristics of biliary tract complications during laparoscopic cholecystectomy: a multi-institutional study. The American Journal of Surgery 1994 167 1 27 34 2-s2.0-0027968108 10.1016/0002-9610(94)90050-7 (Pubitemid 24264141)
28. Barone D., Onetto M., Conio M., Paganuzzi M., Saccomanno S., Aste H., Pugliese V., CA 19-9 assay in patients with extrahepatic cholestatic jaundice. International Journal of Biological Markers 1988 3 2 95 100 2-s2.0-0023994218
29. Bhat K., Wang F., Ma Q., Li Q., Mallik S., Hsieh T.-C., Wu E., Advances in biomarker research for pancreatic cancer. Current Pharmaceutical Design 2012 18 17 2439 2451 2-s2.0-84860434801
30. Abdel-Misih S. R. Z., Hatzaras I., Schmidt C., Saab T.-B., Klemanski D., Muscarella P., Melvin W. S., Ellison E. C., Bloomston M., Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Annals of Surgical Oncology 2011 18 4 1116 1121 2-s2.0-79955854559 10.1245/s10434-010-1397-1
31. Montgomery R. C., Hoffman J. P., Riley L. B., Rogatko A., Ridge J. A., Eisenberg B. L., Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Annals of Surgical Oncology 1997 4 7 551 556 2-s2.0-0031242791 (Pubitemid 127725501)
32. Carpelan-Holmström M., Louhimo J., Stenman U.-H., Alfthan H., Haglund C., CEA, CA 19-9 and CA 72-4 improve the diagnostic accurary in gastrointestinal cancers. Anticancer Research 2002 22 4 2311 2316 2-s2.0-0036339027 (Pubitemid 34857058)
33. Banfi G., Bravi S., Ardemagni A., Zerbi A., CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer. International Journal of Biological Markers 1996 11 2 77 81 2-s2.0-0029974175 (Pubitemid 26177671)
34. Glenn J., Steinberg W. M., Kurtzman S. H., Steinberg S. M., Sindelar W. F., Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. Journal of Clinical Oncology 1988 6 3 462 468 2-s2.0-0023851586 (Pubitemid 18090693)
35. Yasue M., Sakamoto J., Teramukai S., Morimoto T., Yasui K., Kuno N., Kurimoto K., Ohashi Y., Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer. Pancreas 1994 9 6 735 740 2-s2.0-0028020349 (Pubitemid 24317826)
36. Katsuragi K., Yashiro M., Sawada T., Osaka H., Ohira M., Hirakawa K., Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. The British Journal of Cancer 2007 97 4 550 556 2-s2.0-34547859624 10.1038/sj.bjc.6603909 (Pubitemid 47258457)
37. Dalal K. M., Woo Y., Galanis C., Gonen M., Tang L., Allen P., Dematteo R., Fong Y., Coit D. G., Detection of micrometastases in peritoneal washings of pancreatic cancer patients by the reverse transcriptase polymerase chain reaction. Journal of Gastrointestinal Surgery 2007 11 12 1598 1606 2-s2.0-36148945290 10.1007/s11605-007-0283-z
38. Dalal K. M., Woo Y., Kelly K., Galanis C., Gonen M., Fong Y., Coit D. G., Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric Cancer 2008 11 4 206 213 2-s2.0-58149472218 10.1007/s10120-008-0483-6
39. Miyazono F., Takao S., Natsugoe S., Uchikura K., Kijima F., Aridome K., Shinchi H., Aikou T., Molecular detection of circulating cancer cells during surgery in patients with biliary-pancreatic cancer. The American Journal of Surgery 1999 177 6 475 479 2-s2.0-0032798535 10.1016/S0002-9610(99)00086-0 (Pubitemid 29331477)
40. Uchikura K., Takao S., Nakajo A., Miyazono F., Nakashima S., Tokuda K., Matsumoto M., Shinchi H., Natsugoe S., Aikou T., Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis. Annals of Surgical Oncology 2002 9 4 364 370 2-s2.0-0036257294 10.1245/aso.2002.9.4.364 (Pubitemid 34496724)
41. Tjensvoll K., Nordgård O., Smaaland R., Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. International Journal of Cancer 2014 134 1 1 8 2-s2.0-84875348371 10.1002/ijc.28134
42. McMillan D. C., Systemic inflammation, nutritional status and survival in patients with cancer. Current Opinion in Clinical Nutrition and Metabolic Care 2009 12 3 223 226 2-s2.0-65549146877 10.1097/MCO.0b013e32832a7902
43. Roxburgh C. S. D., McMillan D. C., Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncology 2010 6 1 149 163 2-s2.0-75149189004 10.2217/fon.09.136
44. Bhatti I., Peacock O., Lloyd G., Larvin M., Hall R. I., Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. The American Journal of Surgery 2010 200 2 197 203 2-s2.0-77955894120 10.1016/j.amjsurg.2009.08.041
45. Aliustaoglu M., Bilici A., Seker M., Dane F., Gocun M., Konya V., Ustaalioglu B. B. O., Gumus M., The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepato-Gastroenterology 2010 57 99-100 640 645 2-s2.0-77955541359
46. An X., Ding P.-R., Li Y.-H., Wang F.-H., Shi Y.-X., Wang Z.-Q., He Y.-J., Xu R.-H., Jiang W.-Q., Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010 15 6 516 522 2-s2.0-77955862760 10.3109/1354750X.2010.491557
47. Crane C. H., Varadhachary G. R., Yordy J. S., Staerkel G. A., Javle M. M., Safran H., Haque W., Hobbs B. D., Krishnan S., Fleming J. B., Das P., Lee J. E., Abbruzzese J. L., Wolff R. A., Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. Journal of Clinical Oncology 2011 29 22 3037 3043 2-s2.0-80051613675 10.1200/JCO.2010.33.8038
48. Tascilar M., Skinner H. G., Rosty C., Sohn T., Wilentz R. E., Offerhaus G. J. A., Adsay V., Abrams R. A., Cameron J. L., Kern S. E., Yeo C. J., Hruban R. H., Goggins M., The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clinical Cancer Research 2001 7 12 4115 4121 2-s2.0-0035671396 (Pubitemid 34044636)
49. Lacobuzio-Donahue C. A., Fu B., Yachida S., Luo M., Abe H., Henderson C. M., Vilardell F., Wang Z., Keller J. W., Banerjee P., Herman J. M., Cameron J. L., Yeo C. J., Halushka M. K., Eshleman J. R., Raben M., Klein A. P., Hruban R. H., Hidalgo M., Laheru D., DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. Journal of Clinical Oncology 2009 27 11 1806 1813 2-s2.0-62249176551 10.1200/JCO.2008.17.7188
50. Winter J. M., Tang L. H., Klimstra D. S., Liu W., Linkov I., Brennan M. F., DêAngelica M. I., Dematteo R. P., Fong Y., Jarnagin W. R., OêReilly E. M., Allen P. J., Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. Annals of Surgery 2013 258 2 331 335 2-s2.0-84880573095 10.1097/SLA.0b013e31827fe9ce
51. Ohtaki T., Shintani Y., Honda S., Matsumoto H., Hori A., Kanehashi K., Terao Y., Kumano S., Takatsu Y., Masuda Y., Ishibashi Y., Watanabe T., Asada M., Yamada T., Suenaga M., Kitada C., Usuki S., Kurokawa T., Onda H., Nishimura O., Fujino M., Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001 411 6837 613 617 2-s2.0-0035978639 10.1038/35079135 (Pubitemid 32531412)
52. Kotani M., Detheux M., Vandenbogaerde A., Communi D., Vanderwinden J.-M., Le Poul E., Brézillon S., Tyldesley R., Suarez-Huerta N., Vandeput F., Blanpain C., Schiffmann S. N., Vassart G., Parmentier M., The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. Journal of Biological Chemistry 2001 276 37 34631 34636 2-s2.0-0035860778 10.1074/jbc.M104847200
53. Masui T., Doi R., Mori T., Toyoda E., Koizumi M., Kami K., Ito D., Peiper S. C., Broach J. R., Oishi S., Niida A., Fujii N., Imamura M., Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochemical and Biophysical Research Communications 2004 315 1 85 92 2-s2.0-10744221941 10.1016/j.bbrc.2004.01.021 (Pubitemid 38175189)
54. Ying H., Elpek K. G., Vinjamoori A., Zimmerman S. M., Chu G. C., Yan H., Fletcher-Sananikone E., Zhang H., Liu Y., Wang W., Ren X., Zheng H., Kimmelman A. C., Paik J.-H., Lim C., Perry S. R., Jiang S., Malinn B., Protopopov A., Colla S., Xiao Y., Hezel A. F., Bardeesy N., Turley S. J., Alan Wang Y., Chin L., Thayer S. P., DePinho R. A., PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF- B-cytokine network. Cancer Discovery 2011 1 2 158 169 2-s2.0-84857735480 10.1158/2159-8290.CD-11-0031
55. Hill R., Calvopina J. H., Kim C., Wang Y., Dawson D. W., Donahue T. R., Dry S., Wu H., PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Research 2010 70 18 7114 7124 2-s2.0-77956925475 10.1158/0008-5472.CAN-10-1649
56. Shroff S., Overman M. J., Rashid A., Shroff R. T., Wang H., Chatterjee D., Katz M. H., Lee J. E., Wolff R. A., Abbruzzese J. L., Fleming J. B., Wang H., The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. Archives of Pathology & Laboratory Medicine 2013 137 11 1619 1626 10.5858/arpa.2012- 0418-OA
57. Maréchal R., Demetter P., Nagy N., Berton A., Decaestecker C., Polus M., Closset J., Devière J., Salmon I., Van Laethem J.-L., High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. The British Journal of Cancer 2009 100 9 1444 1451 2-s2.0-65549096660 10.1038/sj.bjc.6605020
58. Ellenrieder V., Adler G., Gress T. M., Invasion and metastasis in pancreatic cancer. Annals of Oncology 1999 10 supplement 4 S46 S50 2-s2.0-0032776694 (Pubitemid 29333394)
59. Duffy M. J., The role of proteolytic enzymes in cancer invasion and metastasis. Clinical and Experimental Metastasis 1992 10 3 145 155 2-s2.0-0026522287
60. Kuliawat R., Klumperman J., Ludwig T., Arvan P., Differential sorting of lysosomal enzymes out of the regulated secretory pathway in pancreatic β -cells. Journal of Cell Biology 1997 137 3 595 608 2-s2.0-0030943904 10.1083/jcb.137.3.595 (Pubitemid 27200663)
61. Tumminello F. M., Leto G., Pizzolanti G., Candiloro V., Crescimanno M., Crosta L., Flandina C., Montalto G., Soresi M., Carroccio A., Bascone F., Ruggeri I., Ippolito S., Gebbia N., Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Anticancer Research 1996 16 4 2315 2319 2-s2.0-9444250436 (Pubitemid 26265584)
62. Folkman J., Watson K., Ingber D., Hanahan D., Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989 339 6219 58 61 2-s2.0-0024549349 (Pubitemid 19115892)
63. Weidner N., Semple J. P., Welch W. R., Folkman J., Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. New England Journal of Medicine 1991 324 1 1 8 2-s2.0-0026083903
64. Itakura J., Ishiwata T., Friess H., Fujii H., Matsumoto Y., Büchler M. W., Korc M., Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clinical Cancer Research 1997 3 8 1309 1316 2-s2.0-0030754056 (Pubitemid 27362391)
65. Niedergethmann M., Hildenbrand R., Wolf G., Verbeke C. S., Richter A., Post S., Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. International Journal of Pancreatology 2000 28 1 31 39 2-s2.0-0033748329
66. Seo Y., Baba H., Fukuda T., Takashima M., Sugimachi K., High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000 88 10 2239 2245 (Pubitemid 30247122)
67. Arafat H. A., Gong Q., Chipitsyna G., Rizvi A., Saa C. T., Yeo C. J., Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. Journal of the American College of Surgeons 2007 204 5 996 1005 2-s2.0-34247511935 10.1016/j.jamcollsurg.2007.01.067 (Pubitemid 46661215)
68. Sharma T., Dhingra R., Singh S., Sharma S., Tomar P., Malhotra M., Bhardwaj T. R., Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors. Mini-Reviews in Medicinal Chemistry 2013 13 4 530 540 2-s2.0-84875339336 10.2174/1389557511313040006
69. Gaya A., Tse V., A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treatment Reviews 2012 38 5 484 493 2-s2.0-84861190138 10.1016/j.ctrv.2011.12.008
70. Rodríguez-Pascual J., Sha P., García-García E., Rajeshkumar N. V., De Vicente E., Quijano Y., Cubillo A., Angulo B., Hernando O., Hidalgo M., A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer. Investigational New Drugs 2013 31 1 14 19 2-s2.0-84873082808 10.1007/s10637-012-9822-x
71. Bloomston M., Frankel W. L., Petrocca F., Volinia S., Alder H., Hagan J. P., Liu C.-G., Bhatt D., Taccioli C., Croce C. M., MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. Journal of the American Medical Association 2007 297 17 1901 1908 2-s2.0-34247862190 10.1001/jama.297.17.1901 (Pubitemid 46707844)
72. Steele C. W., Oien K. A., McKay C. J., Jamieson N. B., Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas 2011 40 8 1165 1171 2-s2.0-80054871772 10.1097/MPA.0b013e3182218ffb
73. Kadera B. E., Li L., Toste P. A., Wu N., Adams C., Dawson D. W., Donahue T. R., MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS ONE 2013 8 8 2-s2.0-84882749158 10.1371/journal.pone.0071978 e71978
74. Zhu Z., Xu Y., Du J., Tan J., Jiao H., Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival. Journal of Surgical Oncology 2014 109 2 89 94 10.1002/jso.23475